XmAb-819

N/A

Report date: 2026/03/19 17:03:28

Base Information

Drug NameXmAb-819

Drug Alias NameXmAb-819

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-Ectonucleotide pyrophosphatase/phosphodiesterase family member 3

TargetsT cell surface glycoprotein CD3Ectonucleotide pyrophosphatase/phosphodiesterase family member 3

Therapy Area/IndicationsKidney NeoplasmsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomFrance +[4]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsKidney NeoplasmsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A